lorazepam has been researched along with paroxetine in 26 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (7.69) | 18.2507 |
| 2000's | 16 (61.54) | 29.6817 |
| 2010's | 8 (30.77) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Fairweather, DB; Hindmarch, I; Kerr, JS; Mahendran, R | 1 |
| Castronovo, V; Ferini-Strambi, L; Montorsi, F; Oldani, A; Rigatti, P; Smirne, S; Zucconi, M | 1 |
| Aldenhoff, JB; Friege, L; Göder, R; Grohmann, R; Treskov, V | 1 |
| Einarson, A; Koren, G; Selby, P | 1 |
| Bell, R; Campbell, C; Green, JF; King, DJ; McCartan, D; Pickering, A; Trimble, K | 1 |
| Bergamasco, B; Cicolin, A; Fattori, E; Guastamacchia, G; Lanotte, MM; Lopiano, L; Makrydakis, G; Mutani, R; Tavella, A; Terreni, A; Torre, E; Zibetti, M | 1 |
| Bailey, JE; Diaper, A; Kendrick, A; Nutt, DJ; Potokar, JP | 1 |
| Clifford, TJ; Neto, GM; Plint, A; Randhawa, N; Reid, SM | 1 |
| Akiyama, K; Hirokane, G; Morita, S; Okawa, M; Saeki, Y; Shimoda, K; Ueda, M; Watanabe, T | 1 |
| Cappelleri, JC; Endicott, J; Fehnel, SE; Feltner, D; Harness, J; Morlock, RJ; Williams, VS | 1 |
| Cantoni, A; De Panfilis, C; Giannelli, MR; Maggini, C; Marchesi, C | 1 |
| Frank, C | 1 |
| Gómez-Grande, ML; Martín-Rodríguez, C; Ortega-Carnicer, J; Portilla-Botelho, M | 1 |
| Brock, J; Cappelleri, JC; Feltner, DE; Harness, J; Morlock, R; Sambunaris, A | 1 |
| Feltner, D; Morlock, RJ; Williams, VS | 1 |
| Crnobaric, C; Kecojevic-Miljevic, S; Lecic-Tosevski, D; Miljevic, CD | 1 |
| Patterson, B; Van Ameringen, M | 1 |
| Ebert, LC; Fornaro, J; Gascho, D; Kraemer, T; Laberke, P; Martinez, RM; Staeheli, SN; Steuer, AE; Thali, MJ | 1 |
| Dolzhenko, AV; Hadi, MA; Jalal, Z; Khan, TM; Yap, WS | 1 |
2 review(s) available for lorazepam and paroxetine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Efficacy and safety of lavender essential oil (Silexan) capsules among patients suffering from anxiety disorders: A network meta-analysis.
Topics: Anti-Anxiety Agents; Anxiety Disorders; Capsules; Humans; Lavandula; Lorazepam; Network Meta-Analysis; Oils, Volatile; Paroxetine; Personality Assessment; Plant Oils; Treatment Outcome | 2019 |
6 trial(s) available for lorazepam and paroxetine
| Article | Year |
|---|---|
The effects of paroxetine, alone and in combination with alcohol on psychomotor performance and cognitive function in the elderly.
Topics: Aged; Aged, 80 and over; Cognition; Double-Blind Method; Ethanol; Flicker Fusion; Humans; Lorazepam; Male; Memory, Short-Term; Middle Aged; Paroxetine; Psychomotor Performance; Reaction Time; Sleep | 1992 |
The differential effects of chlorpromazine and haloperidol on latent inhibition in healthy volunteers.
Topics: Acoustic Stimulation; Adolescent; Adult; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Attention; Chlorpromazine; Cognition; Double-Blind Method; Haloperidol; Humans; Learning; Lorazepam; Male; Neuropsychological Tests; Paroxetine; Psychomotor Performance; Space Perception | 2001 |
A validation of the 7.5% CO2 model of GAD using paroxetine and lorazepam in healthy volunteers.
Topics: Administration, Inhalation; Adult; Anti-Anxiety Agents; Anxiety Disorders; Carbon Dioxide; Double-Blind Method; Humans; Lorazepam; Male; Paroxetine; Psychiatric Status Rating Scales; Reference Values; Selective Serotonin Reuptake Inhibitors; Time Factors; Treatment Outcome | 2007 |
High plasma concentrations of paroxetine impede clinical response in patients with panic disorder.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Asian People; Azepines; Diagnostic and Statistical Manual of Mental Disorders; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Monitoring; Female; Humans; Hypnotics and Sedatives; Lorazepam; Male; Middle Aged; Panic Disorder; Paroxetine; Psychiatric Status Rating Scales; Regression Analysis; Sleep Initiation and Maintenance Disorders; Time Factors | 2007 |
Effect of pharmacological treatment on temperament and character in panic disorder.
Topics: Adult; Anxiety; Character; Citalopram; Female; Follow-Up Studies; GABA Modulators; Humans; Lorazepam; Male; Panic Disorder; Paroxetine; Personality Disorders; Remission Induction; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Temperament | 2008 |
Clinical evaluation of the Daily Assessment of Symptoms-Anxiety (DAS-A): a new instrument to assess the onset of symptomatic improvement in generalized anxiety disorder.
Topics: Adult; Anti-Anxiety Agents; Anxiety Disorders; Double-Blind Method; Female; Humans; Lorazepam; Male; Middle Aged; Paroxetine; Sensitivity and Specificity | 2009 |
18 other study(ies) available for lorazepam and paroxetine
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Topics: Algorithms; Blood Proteins; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding; Statistics as Topic; Tissue Distribution | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility | 2010 |
Sleep-related painful erections: clinical and polysomnographic features.
Topics: Adrenergic beta-Antagonists; Adult; Amitriptyline; Humans; Lorazepam; Male; Middle Aged; Narcolepsy; Paroxetine; Penile Erection; Polysomnography; Propranolol; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Sexual Dysfunctions, Psychological; Sleep Stages; Sleep, REM | 1996 |
Association of paroxetine with suicide attempt in obsessive-compulsive disorder.
Topics: Adult; Anti-Anxiety Agents; Antipsychotic Agents; Humans; Lorazepam; Male; Methotrimeprazine; Obsessive-Compulsive Disorder; Paroxetine; Promethazine; Selective Serotonin Reuptake Inhibitors; Suicide, Attempted | 2000 |
Discontinuing antidepressants and benzodiazepines upon becoming pregnant. Beware of the risks of abrupt discontinuation.
Topics: Anti-Anxiety Agents; Antidepressive Agents; Evidence-Based Medicine; Female; Humans; Informed Consent; Lorazepam; Paroxetine; Patient Education as Topic; Preconception Care; Pregnancy; Risk Factors; Safety; Substance Withdrawal Syndrome | 2001 |
Effects of deep brain stimulation of the subthalamic nucleus on sleep architecture in parkinsonian patients.
Topics: Antidepressive Agents; Disorders of Excessive Somnolence; Electric Stimulation Therapy; Female; Humans; Lorazepam; Male; Middle Aged; Nocturnal Myoclonus Syndrome; Parkinsonian Disorders; Paroxetine; Polysomnography; Preoperative Care; Prospective Studies; Sertraline; Sleep Stages; Subthalamic Nucleus; Surveys and Questionnaires; Videotape Recording | 2004 |
Use of single-dose activated charcoal among Canadian pediatric emergency physicians.
Topics: Acetaminophen; Adolescent; Antidotes; Canada; Charcoal; Child, Preschool; Cross-Sectional Studies; Digoxin; Emergency Service, Hospital; Guideline Adherence; Health Care Surveys; Humans; Ibuprofen; Iron Compounds; Lorazepam; Male; Paroxetine; Poisoning; Time Factors | 2006 |
Development and evaluation of the Daily Assessment of Symptoms - Anxiety (DAS-A) scale to evaluate onset of symptom relief in patients with generalized anxiety disorder.
Topics: Adult; Anti-Anxiety Agents; Anxiety Disorders; Female; Focus Groups; Health Status; Humans; Kaplan-Meier Estimate; Lorazepam; Male; Paroxetine; Personality Inventory; Predictive Value of Tests; Psychometrics; Regression Analysis; Reproducibility of Results; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Surveys and Questionnaires; Treatment Outcome | 2008 |
Recognition and treatment of serotonin syndrome.
Topics: Aged, 80 and over; Anticonvulsants; Depressive Disorder; Drug Interactions; Humans; Lorazepam; Male; Paroxetine; Selective Serotonin Reuptake Inhibitors; Serotonin Syndrome | 2008 |
[Paroxetine-induced severe hyponatremic rhabdomyolisis].
Topics: Cations; Coma; Depressive Disorder; Diagnosis, Differential; Epilepsy, Tonic-Clonic; Female; Humans; Hyponatremia; Lorazepam; Middle Aged; Muscle Cells; Paroxetine; Rhabdomyolysis; Saline Solution, Hypertonic; Selective Serotonin Reuptake Inhibitors | 2008 |
Psychometric evaluation of a visual analog scale for the assessment of anxiety.
Topics: Adult; Anxiety Disorders; Female; Humans; Lorazepam; Male; Middle Aged; Paroxetine; Psychometrics; Randomized Controlled Trials as Topic; Reproducibility of Results; Time Factors | 2010 |
A rare case of male hysteria - hemiparesis successfully treated with amitriptyline.
Topics: Adult; Amitriptyline; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Brain; Bromazepam; Depressive Disorder, Major; Humans; Hysteria; Lorazepam; Magnetic Resonance Imaging; Male; Paresis; Paroxetine; Treatment Outcome | 2011 |
Topiramate augmentation in a patient with obsessive-compulsive disorder.
Topics: Adult; Anti-Anxiety Agents; Anticonvulsants; Citalopram; Drug Synergism; Fear; Female; Fructose; Humans; Lorazepam; Obsessive-Compulsive Disorder; Paroxetine; Recurrence; Selective Serotonin Reuptake Inhibitors; Sertraline; Topiramate; Treatment Refusal | 2015 |
Development of CT-guided biopsy sampling for time-dependent postmortem redistribution investigations in blood and alternative matrices--proof of concept and application on two cases.
Topics: Autopsy; Chromatography, Liquid; Desvenlafaxine Succinate; Equipment Design; Female; Flupenthixol; Forensic Toxicology; Humans; Image-Guided Biopsy; Lorazepam; Middle Aged; Paroxetine; Postmortem Changes; Robotics; Tandem Mass Spectrometry; Time Factors; Tissue Distribution; Tomography, X-Ray Computed; Venlafaxine Hydrochloride | 2016 |